ERBB2 and cancer: The NCT02675829 study, which is currently enrolling participants, is a clinical trial investigating the use of T-DM1 in patients with HER2-amplified or mutant cancers, including solid tumor cancers, lung cancer, bladder cancer, and urinary tract cancers.